

For Immediate Release



## PRESS RELEASE

---

### **Ceva launches Kesium<sup>®</sup> (amoxicillin and clavulanate potassium tablets) a generic bioequivalent to Clavamox<sup>®</sup> chewable tablets**

**(LENEXA, Kan - February 11, 2025)** Kesium<sup>®</sup>, the first chewable tablet bioequivalent to Clavamox<sup>®</sup> chewable tablets is now available in the U.S.

Introduced by Ceva Animal Health, Kesium<sup>®</sup> is a broad-spectrum oral antibiotic (amoxicillin) with an  $\beta$ -lactamase inhibitor (clavulanate potassium) for the treatment of bacterial infections in dogs and cats. Ceva is launching a portfolio of anti-infectives with the introduction of Kesium<sup>®</sup>.

As the first chewable branded alternative to Clavamox<sup>®</sup> Chewable tablets, Kesium<sup>®</sup> offers the same trusted efficacy and safety profile with convenient dosing options. This product provides an affordable option for veterinarians seeking effective, broad-spectrum coverage for indicated skin and soft tissue infections.

"We believe Kesium<sup>®</sup> will quickly become a go-to choice for treating indicated dermatological, soft tissue, and periodontal infections for dogs as well as dermatological, soft tissue, and urinary tract infections for cats. The affordable price of a generic combined with this trusted combination of oral antibiotic and  $\beta$ -lactamase inhibitor will be appreciated by veterinarians and pet owners," Dr Susanne Heartsill, DVM, DABVP (Canine and Feline Practice), US Director, Companion Animal Veterinary Services.

The chewable, pork flavored tablets are available in 4 strengths: 62.5 mg for dogs and cats and 125 mg, 250 mg and 375 mg for dogs. In a laboratory study conducted with cats, Kesium<sup>®</sup> was accepted in 74% of instances.\*

# # #

#### **Important information:**

**Indications in Dogs:** Skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/ juvenile and deep pyoderma due to susceptible strains of the following organisms:  $\beta$ -lactamase-producing *Staphylococcus aureus*, non- $\beta$ -lactamase-producing *Staphylococcus aureus*, *Staphylococcus spp.*, *Streptococcus spp.*, and *E. coli*. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria. Kesium has been shown to be clinically effective for treating cases of canine periodontal disease.

## For Immediate Release

Continued

**Indications in Cats:** Skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: *β*-lactamase-producing *Staphylococcus aureus*, non-*β*-lactamase-producing *Staphylococcus aureus*, *Staphylococcus spp.*, *Streptococcus spp.*, *E. coli*, and *Pasteurella spp.* Urinary tract infections (cystitis) due to susceptible strains of *E. coli*. Urinary tract infections (cystitis) due to susceptible strains of *E. coli*.

**IMPORTANT SAFETY INFORMATION:** Kesium® Chewable Tablets contain a semisynthetic penicillin (amoxicillin) and have the potential for producing allergic reactions. People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to Kesium® Chewable Tablets. Do not use in animals with a history of an allergic reaction to any of the penicillins or cephalosporins. If an allergic reaction occurs, administer epinephrine and/or steroids. Refer to the product insert for complete details.

\*Laboratory study. Data on file.


Kesium® is a registered trademark of Ceva Santé Animale S.A.

Clavamox is a registered trademark of GlaxoSmithKline, LLC.

### About Ceva Animal Health, LLC

Ceva Animal Health, LLC (Ceva) is the 5th largest global animal health company, led by experienced veterinarians, whose mission is to provide innovative health solutions to ensure the highest level of care and well-being. Our portfolio includes preventive medicine such as vaccines, pharmaceutical and animal welfare products for farm and companion animals. We also offer equipment and services to provide the best experience for our customers. With 6,500 employees located in 47 countries, Ceva strives daily to bring to life its vision as a OneHealth company: "Together, beyond animal health".

Product Image:



**Press Contact:** Jody Donohue, APR, Communications Manager

Mobile: 913.333.6329

email: [jody.donohue@ceva.com](mailto:jody.donohue@ceva.com)